Companies › NiKang Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NKT5097 CDK2/CDK4 dual degrader | CDK2, CDK4 | Phase 1 | HR+ Breast Cancer | Jul 2027 |
| NKT3964 CDK2 Degrader | CDK2 | Phase 1 | Solid Tumor | Jan 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07029399 | NKT5097 | Phase 1 | HR+ Breast Cancer | Oncology | Jul 2027 |
| NCT06586957 | NKT3964 | Phase 1 | Solid Tumor | Oncology | Jan 2029 |
Pfizer Avenzo Therapeutics Chia Tai Tianqing Pharmaceutical Group AstraZeneca BeiGene Eilean Therapeutics Incyclix Bio Novartis Pharmacosmos BeOne Medicines
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.